The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Plenty of products.
https://novacyt.com/products-and-solutions/
There are a raft of LFTs for bacteria infections, virus and inflammations. The DHSC just needs to pay up and hopefully buy up some of these tests that GPs could use saving NHS trusts the time and paperwork of having to be diagnosed by taking samples in hospital labs when they may not be required.
Blimey presuming we still have the green box called globetrotter battering away
http://novacyt.com/wp-content/uploads/2022/04/Investor-Presentation-28.04.2022-Website.pdf
Yep no plan!!!!! Whether anybody agrees or disagrees with the 100 mil projection. They have a plan and it's laid out here perhaps they've chosen insect borne testing as there's a gap in the market that the big boys aren't interested in.
globe - could not have put it better.
unfortunately salad man has been a disaster - but hey lets give him a pay rise.
the markets are tough and going to get a lot worse. salad will not cut it. wafting 3 figure million revenue with no substance to back it up ain't going to work.
need definite products/brand /target market strategy for base business
need to be cashing in on monkey pox - as a global responder
Would not be to eager " to go in Big" if the price falls under a quid. In my view the possibility of this happening is real. What is disconcerting is in my view the lack of visibility in earnings and the apparent inaction by the BOD to give the market a clear and definite pathway of where the future revenue streams will come from. Being first of the block and new products are fine but what the company needs are consistent definite contracts which have been lacking for quite a while now. BOD certainly not shareholder friendly. They still have to justify their increased pay packet with definite action and results.
Glassdoor is not exactly the most reliable source of information about the true state of affairs in any company. People with a grudge are 10 times more likely to post on it. There are also no safeguards against one individual posting multiple times (sound familiar Amazon and Ebay!).
I certainly would not be taking investment decisions based on that.
I wasn't overly concerned about the dispute until recently. Because I only focused on the contract being watertight(ish) so no big settlement if Nova lost (or won). But reading thro the reviews on Glassdoor (again) noticed a trend the recent bad ones are typical of a comp with bad management, the bad ones from early 2021 (when people started posting) are more disturbing. I hear alarm bells when I read 'unprofessional' 'disorganised' 'bullying' and the bad one 'marketing and sales has zero accountability'. That smacks of a cowboy culture back then and that means someone may well have made documented commitments outside of the contract that weren't/couldn't be delivered.
But it's not nec a bad thing if true, I wouldn't expect too big a judgment against Nova, it will be the reputational damage that will hurt the SP, it's evidence of prev bad management, and current bad management who didn't deal with it. It may well be the crow-bar needed to oust the current bunch and/or get Nova to turn that corner.
TBH if the SP goes under a quid I'm really tended to go in big (for me) on it
And never anyone perusing the Chinese for billions of pounds of tests not fit for purpose binned by the FDA and all that PPE costing a fortune to purchase and I believe 5 million a week ? To store , a farce.
https://twitter.com/CharlieBurns9/status/1556637492748734466?s=20&t=WbaaX9OkcfCMtaqQJQ70Wg
The dispute thing Kaeren is odd, I agree. Out of all those billions spent with 100s of suppliers, Nanopore, ODX, ABDX and NCYT had issues. I’ve never found a list detailing out all DHSC disputes so no idea if these are the only companies. Have there been any overseas companies apart from Novacyt, again who knows.
Yes I saw that BYP but see the article I have just posted , there must be a diff that neither of us understand :(
Hi Kaeren…biofortuna was discussed last week. They developed worlds first freeze dried PCR in 2014. I don’t know enough about the science but from a layman’s point of view the technology has been around for a long time.
https://www.nsmedicaldevices.com/news/biofortuna-obtains-fda-510k-approval-for-sspgo-hla-pcr-kits-270214-4185522/
21.59 , yes :)
Sorry meant to attach this , so in 2021 it hadn't been achieved , is this what we have achieved ? I'm so not techie so don't know !
https://news.northwestern.edu/stories/2021/06/covid-19-pcr-tests-can-be-freeze-dried/
You know my thoughts on most of those points
BYP. The DHSC dispute may well have happened to any other competitor to shoehorn the favoured few thru the backdoor. Look at Randox who got contract after contract and the connection with the Tory party. Look at ABDX , Nanopore , ODX , we just unfortunately have been shafted for a much larger amt and DHSC obviously intend to string it out. I believe we will win.
Re Ajan , there is no proof what so ever that what was printed was true and if Novacyt were concerned at all they would have withdrawn the product from CTDA certification. Do not for one moment think I condone the position Novacyt put the company in , it doesn't take a genius to research historical events. However Roche also saw fit to employ him for several years and several other well known institutions.
I cannot argue who was first off the draw with the Moneypox assays as I have insufficient info , all I know is the clades and mutations were still being established and several companies put assays on the market prior to this happening. How good are they ? I don't know.
Re dry ice , I don't pretend to know what they are telling us they have achieved , what differentiates this product is is not clear to me, I understand the usage in hot climates , the ease of transportation, but as you say , it appears to have been on the market for a while. Yet there are articles discussing the need for it in 2020 , so perhaps it is me who doesn't understand.
Kaeren, for all we know, Biosynex might have completely sold out. There’s plenty of iis in the past who held more than 3% yet never notified the market (These can be found in the RNSs from 2019 onwards).
Reference the science prospective, I don’t know enough about who has the best reagents and tests. Everyone company claims to be a first responder or world leading but Novacyt certainly weee nowhere near the fastest at bringing out the Monkeypox test. 8 years behind the quickest company lies freeze dried PCRs as I mentioned last week. If they are great then why the Ajan Reginald accusations on the tests in private eye. If they are great, why the DHSC claim. If they are great, why are we not selling. If we are great, why no takeover at MCAP under cash levels. If the products great, people will buy anyway but that isn’t evident from the figures. It’s all very well a few commentators on here claiming it, but unfortunately it means nothing at present.
Hello BYP, it was posted because they still hold approx 4.5 % of Novacyts shares and they sold under 20 %. I posted as I think it is useful to have an idea what a competitor who holds a sizeable lump of Novacyt shares is up to. Yes it highlights the disparities between the two companies and to say it is frustrating is an understatement. I wouldn't be surprised if they raised additional funds and swallowed us whole !
Quite frankly as no partnership has been publicised it would not shock me to learn that there has been no communication between the two companies. D.A needs to start some M&A fast or he will find himself being made redundant by the likes of Bio or a similar outfit. They have streamlined , assume got rid of whom they wanted and ripe for a take out. Not an attempt to ramp in any way , but they have superb tests , R& D , work with world renowned names and managed to earn diddly squat H1. Just imo.
I’m not sure what the point is that is trying to be made?
1/ We aren’t Biosynex and this is a Novacyt board
2/ Biosynex no longer see Novacyt as an investment case (hence they sold their shares as rock bottom prices).
3/ Biosynex are financially much better equipped for MA, and to action out their strategy, 206m euro profit in 2021 and can afford to pay out on dividends and don’t have a £130m legal case hanging over their heads.
4/ Their MCAP is only 50m euros more than ours and arguably should be a lot more than Novacyt.
5/ biosynex are a million miles away from Novacyt. People read ‘point of care’ or ‘decentralised’ and put 2+2 together and come up with 5.
6) this share is dead, no volume, ATs dried up, trading dissapeared.
7) no matter how many times tata show an express machine, we know the revenues in h1 2022 are woeful and no covid revenues are worse than pre covid levels.
8) DA should be ashamed to take a salary
9) our board are crap.
Kaerens text nearly all translated
The Diagnostic BU will be unified from trade to marketing via R&D and production under the direction of Thierry Paper, Deputy Chief Executive Officer.
"Biosynex played a major role during the COVID-19 crisis by providing innovative diagnostic solutions to various health professionals. We are now projecting ourselves as a reference French player in different segments of in vitro diagnosis: rapid tests, molecular biology, delocalised biology (Point of care) and monitoring of biotherapies. To achieve our objectives, we are committed to a proactive innovation policy by strengthening our Research & Development capacities and multiplying strategic partnerships and external growth. At the same time, we are expanding our sales network through the creation of subsidiaries or the acquisition of distributors. The metamorphosis of Biosynex into a multinational medtech is underway. This evolution has led us to adapt our internal organisation by creating two poles: diagnosis and pharmacy. Personally, I am honoured to expand my responsibilities and take over the management of the Diagnostic division 17 years after founding this company with Larry Abensur and Thomas Lamy. I will ensure the fulfilment of everyone in a mature structure but who has kept his youth and his desire to go from
….much less risk than Novacyt.
Their share price dropped 30 percent in four months and shows no sign of stopping. This is a holding comms just like DAs £100m in 5 years. Sounds like they have their very own salad man too. But Biosynex is obviously
Meanwhile back at the ranch .....
https://www.linkedin.com/posts/biosynex-group_laboratoire-biosynex-diagnostic-activity-6960248295411621892-8UtX
Well, this share has officially flat lined in the uk.
I don’t know what is more useless in life……CEO David Allmond or CEO David Allmonds comb……..it’s a close call (Apologies to Will Smith fans).
Did you know that the last time the volume was lower than today (10,480) was January 17th 2020 (10,310).